Two aspects relevant to any newly approved multiple sclerosis treatment with immunomodulatory properties are highlighted with this case: first, possible rebound of disease activity after discontinuation; second, the occurrence of a tumor as a possible treatment-related complication.
Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Marchioninistr 15, 81377 Munich, Germany.
Arch Neurol. 2012 Feb;69(2):262-4
© Galenicom 1999-2013